ArticleFrontiers in pharmacology2023
How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action.
Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Stated Preferences for Systemic Treatments for Prostate Cancer: A Targeted Review of the Discrete-Choice Experiment Literature.The patient · 2026Pooled it
- Multicriteria decision analysis in the Italian healthcare context: a review of applications and methodological approaches.Frontiers in public health · 2026Pooled it
- Patient Preferences in Neuromuscular Diseases: Insights for Future Drug Development.JIMD reports · 2026Article
- From Concept to Claim: An Integrated Lifecycle Roadmap (ILR) for Patient-Centric Endpoints in Clinical Trials and Real-World Evidence.Healthcare (Basel, Switzerland) · 2026Review
- Challenges in Conducting Quantitative Patient-Centered Benefit-Risk Assessments: A Case Study in Ph + ALL with Immature Efficacy Data.Therapeutic innovation & regulatory science · 2026Article
- Multi-stakeholder use of patient experience data (PED): current state and future opportunities for the application of PED to inform decision-making.Journal of patient-reported outcomes · 2026Review
- Editorial: Regulatory science: addressing uncertainties in medicines development, evaluation and use.Frontiers in medicine · 2026Article
- How Patients Can Contribute to the Assessments of Health Technologies.Journal of market access & health policy · 2025Article
- Identification and Description of Regulatory and Health Technology Assessment Agencies' Guidance Related to Patient Experience Data in North America, Europe, and Asia Pacific.Therapeutic innovation & regulatory science · 2025Article
- Article
- Putting the Choice in Choice Tasks: Incorporating Preference Elicitation Tasks in Health Preference Research.The patient · 2025Article
- Exploring Patient Preference Information in Clinical Research and Decision Models: An Investigative Survey.Patient preference and adherence · 2025Article
- A genuine need or nice to have? Understanding HTA representatives' perspectives on the use of patient preference data.International journal of technology assessment in health care · 2024Article
- COVID-19 Vaccination Reactions and Risk of Breakthrough Infections Among People With Diabetes: Cohort Study Derived From Community Reporters.JMIR diabetes · 2024Article
- From Innovator Result-driven to Multi-actor Impact-oriented Public-Private Partnerships: Integrating the Patient Perspective.Handbook of experimental pharmacology · 2024Review
- Patient preferences for inflammatory bowel disease treatments: protocol development of a global preference survey using a discrete choice experiment.Frontiers in medicine · 2024Article
- Navigating a transforming landscape: the evolving role of pharmacovigilance physicians in drug development and implications for future challenges and training requirements.Frontiers in drug safety and regulation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.